Beijing, China – 14 Sep 2026 – The Center for Medical Device Evaluation (CMDE), the technical review arm of China’s National Medical Products Administration (NMPA), announced an open public consultation on the “Guidance Principles for the Registration Review of Artificial Intelligence Medical Devices (Revised Edition 2026) (Draft for Public Comment),” with stakeholder feedback due by 12 October 2026.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CMDE, under NMPA (China) |
| Action Type | Open public consultation on draft registration review guidance |
| Document | Guidance Principles for the Registration Review of Artificial Intelligence Medical Devices (Revised Edition 2026) (Draft for Public Comment) |
| Issuance Date | 14 Sep 2026 |
| Comment Deadline | 12 Oct 2026, via email using the official feedback form |
| Contact | Peng Liang — +86‑10‑86452602 — pengliang@cmde.org.cn |
| Next Steps | CMDE to review submitted comments and finalize the 2026 revised guidance |
Guidance Profile & Regulatory Background
- Revision Mandate: The revision was organized by CMDE in accordance with the NMPA’s standing program for the development and amendment of medical device registration review guidance documents, reflecting the agency’s ongoing effort to modernize technical review requirements for a rapidly evolving technology class.
- Scope: The guidance governs registration review of artificial intelligence medical devices — software and devices incorporating AI/ML algorithms used for purposes such as medical image analysis, decision support, and clinical workflow assistance — establishing review expectations for safety, efficacy, and quality across the product lifecycle.
- Consultation Materials: Two attachments accompany the notice: the draft revised guidance (Attachment 1) and a standardized feedback form (Attachment 2), both downloadable from CMDE’s website.
- Submission Channel: Comments and suggestions must be completed on the feedback form and emailed to the designated CMDE contact before the 12 October 2026 deadline.
- Source: cmde.org.cn official notice
Market Impact & Outlook
- Sector Significance: AI medical devices are among the fastest‑growing segments of China’s MedTech industry, spanning AI‑assisted imaging diagnostics, triage and workflow software, and decision‑support algorithms; a revised registration review framework directly shapes time‑to‑market for domestic AI startups and multinational device companies alike.
- Compliance Relevance: Developers with pending or planned Class II/III AI device registrations should review the draft early and assess potential impacts on validation datasets, algorithm change control, and clinical evaluation strategies already in their dossiers.
- Industry Participation Window: Stakeholders have approximately four weeks to submit structured feedback — an opportunity for AI‑MedTech companies, hospitals, research institutions, and testing bodies to help shape review expectations before the guidance is finalized.
- Regulatory Trajectory: The 2026 revision continues NMPA’s pattern of periodically updating its AI medical device guidance to keep pace with algorithm advances and international regulatory practice; the final version, key changes from prior editions, and the effective date have not yet been disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of the draft guidance, and its potential impact on AI medical device registration in China. Actual outcomes may differ due to risks including changes arising from the public consultation process, final agency determinations, and shifts in regulatory policy or technology standards.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/flfg/zdyz/zqyjg/20260914160636102.html